본문 바로가기 주메뉴 바로가기

제품소개

제품상세페이지

Proteogenix

[Proteogenix] SARS-CoV-2 RBD of Spike protein, L452R, T478K – lineage B.1.617.2 – Indian Delta Variant

Cat-No. PX-COV-P061


Proteogenix는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.




제품 설명 


SARS-CoV-2 RBD of Spike protein, L452R, T478K – lineage B.1.617.2 – Indian Delta Variant

 



제품 번호

 

PX-COV-P061

 



제품 특징


Product nameSARS-CoV-2 RBD of Spike protein, L452R, T478K – lineage B.1.617.2 – Indian Delta Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
Sequence  YP_009724390.1
Molecular weight35kDa
BufferPBS, pH7.5
FormLiquid
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
ApplicationsELISA,WB
Fragment TypeSpike protein fragment
Aliases /SynonymsB.1.617.2, VOC21APR-02, G/452R.V3, Indian variant, Delta variant
ReferencePX-COV-P061
NoteFor research use only. Not suitable for human use.


Description of SARS-CoV-2 RBD of Spike protein, L452R, T478K – lineage B.1.617.2 – Indian Delta Variant

General information on SARS-CoV-2 RBD of Spike protein, L452R, T478K – lineage B.1.617.2 – Indian Delta Variant protein

There are currently three circulating clades of lineage B.1.617 – B.1.617.1, B.1.617.2, and B.1.617.3, shown in chronological order of detection. Although these clades display different mutation profiles, all were initially detected in India and have since spread to other continents. Of the three clades, lineage B.1.617.2 carrying receptor-binding domain mutations L452R and T478K is the one causing more concern among the scientific community and governments.
Public Health England (PHE) has recently escalated lineage B.1.617.2 from variant under investigation (VUI) to variant of concern – VOC21APR-02 – due to the steep increase of cases in the UK. In early May 2021, the number of cases of this variant with a travel history in India already represented a minority of the total amount of B.1617.2 cases detected in the country. Data suggests a sustained spread of the new variant and hints to its higher infectivity in comparison to other circulating variants of SARS-CoV-2. Although the absolute number of cases remains low, the spread rate of this variant is very high. These findings suggest variant B.1.617.2 may possess transmissibility similar to that of B.1.1.7, one of the most abundant variants of the virus circulating in the UK since September 2020. But it is still unclear if this variant will outcompete the UK strain.
Mutation L452R has been previously detected in two other high abundance variants circulating in the US (lineages B.1.427 and B.1.429). This mutation has been associated with weaker neutralization of the virus by convalescent plasma. However, the available data is still insufficient to understand how this amino acid change might affect vaccine efficiency. Less data is available on the effects of mutation T478K. This amino acid change occurs in the region of interaction between the virus and the human ACE2 receptor. Several lineages of SARS-CoV-2 have been shown to carry this mutation, namely lineage B.1.1.519 (US/Mexico lineage). Moreover, several reports indicate that its abundance among circulating variants has shown a marked increase since January 2021. To date, there are no reports regarding the effects of this change on the transmissibility and immune evasion ability of SARS-CoV-2. For this reason, more functional studies are necessary to determine the potential effect of these combined RBD mutations on COVID-19 vaccine and drug efficiency.




QC & Validation Data


SDS-PAGE for SARS-CoV-2 RBD of Spike protein, L452R, T478K – lineage B.1.617.2 – Indian Delta Variant




Publications


Richel E, Wagner JT, Klessing S, Di Vincenzo R, Temchura V and Überla K (2023) Antigen-dependent modulation of immune responses to antigen-Fc fusion proteins by Fc-effector functions. Front. Immunol. 14:1275193. doi: 10.3389/fimmu.2023.1275193

- Hubert Bernauer, Anja Schlör, Josef Maier, Norbert Bannert, Katja Hanack, Daniel Ivanusic, tANCHOR fast and cost-effective cell-based immunization approach with focus on the receptor-binding domain of SARS-CoV-2, Biology Methods and Protocols, Volume 8, Issue 1, 2023, bpad030, https://doi.org/10.1093/biomethods/bpad030

- Winklmeier S, Rübsamen H, Özdemir C, Wratil PR, Lupoli G, Stern M, Schneider C, Eisenhut K, Ho S, Wong HK, Taskin D, Petry M, Weigand M, Eichhorn P, Foesel BU, Mader S, Keppler OT, Kümpfel T and Meinl E (2024) Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva. Front. Immunol. 15:1330864. doi: 10.3389/fimmu.2024.1330864




ProteoGenix의 모든 제품들을 만나보세요!

 

Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"